Carlyle Group will purchase a 20% stake in Indian billionaire Ajay Piramal’s pharmaceutical business, according to an exchange filing.
The private equity fund will pay $490 million for the holding, valuing the business at an enterprise value of $2.7 billion. In addition to helping expand capacity of the pharmaceutical operations, the Piramal group will use the money to repay some of parent Piramal Enterprises Ltd.’s debt, the filing said.
“This infusion of funds will further strengthen our balance sheet and provide us with a war chest for the next phase of our strategy,” Ajay Piramal, chairman of Piramal Enterprises, said in the filing.
In May, Carlyle agreed to buy up to 74% of SeQuent Scientific, the largest pure-play animal healthcare company in India.
Source: Bloomberg
Can’t stop reading? Read more
Toyota’s $42bn bid to simplify empire draws private equity interest
Toyota’s $42bn bid to simplify empire draws private equity interest Toyota Chairman Akio Toyoda is...
Bain Capital and KPS circle Iveco’s €1.5bn defence unit as private equity interest in military assets surges
Bain Capital and KPS circle Iveco’s €1.5bn defence unit as private equity interest in military...
Capital Group and KKR win SEC nod for hybrid credit funds aimed at retail investors
Capital Group and KKR win SEC nod for hybrid credit funds aimed at retail investors Capital Group...